Patents

1) SD2008-289 - G alpha i - GIV Interface as a Novel Therapeutic Target. (Ghosh, Garcia-Marcos, M., and Farquhar, M.G.).

2) SD2008-289 – Tumoral GIV as a novel biomarker for prognostication in carcinomas. (Ghosh, P., Garcia-Marcos, M., and Farquhar, M.G.). Licensed antibody production (for research purpose) with Millipore Inc. Licensing underway (for diagnostics purposes) with Roche Diagnostics.

3) SD2008-289 - GIV as a serum biomarker for metastatic progression of carcinomas. (Ghosh and Garcia-Marcos).

4) SD2010-066- A Marker and Therapeutic Target for the PI3K Pathway. Licensing completed with Roche Diagnostics (for diagnostics applications) and with Millipore Inc. (for research applications).

5) SD2013-019: A Novel Diagnostic and Therapeutic Target within the Wnt Pathway- (Molecular Basis for Aberrant Signal Amplification in Leukemia, Lymphomas, Solid tumors (breast/Colon) during early oncogenesis and during developmental disorders of the brain). Licensed with Millipore Inc. (for research applications).

6) SD2013-243: Title of Invention A Blood Test to Prognosticate Progression-Free and Overall Survival in Cancer Patients.  Licensing underway with a San Diego-based Biotech Company.

7) SD2014-148: A Method to Predict and Treat Liver Fibrosis and other Fibrogenic Disorders. Licensing underway with Ventana Inc (a branch of Roche Diagnostics).

8) SD2014-186: G-alpha, interacting vesicle associated protein (giv) as a prognositic in stage ii colorectal cancer. Joint IP with Ventana Inc (a branch of Roche Diagnostics).

9) SD-2014-259  - Detection and Treatment of GIV-associated Cancer.

10) SD2014-283-1 - Method to assemble, visualize and measure RTK-G protein complexes in cells.